Combination of ZYNLONTA® and glofitamab (COLUMVI®) shows durable complete responses and manageable safety profile in Phase 1b study.
Combination of ZYNLONTA® and glofitamab (COLUMVI®) shows durable complete responses and manageable safety profile in Phase 1b study.
This approval adds a key anti-inflammatory eye drop to Amneal’s Affordable Medicines portfolio, with a commercial launch planned …
June 11 reveals critical progress across cell and gene therapies, metabolic disease drug research, and strategic industry partnerships …
June 10 sees robust momentum in biotechnology with novel therapeutic developments, advanced clinical trials, key industry events, and …
Significant biotech advancements and industry collaborations define early June with a focus on live biotherapeutics, liquid biopsies, and …
Early clinical successes, new research on immune toxicities, and expanding partnerships underscore the evolving landscape of cell and …
Big pharma pursues targeted expansion while trials in radiopharmaceuticals and immunotherapy highlight the breadth of innovation across cancer, …
Sanofi’s acquisition of Blueprint Medicines, Eli Lilly’s gene-editing push, and several cross-continental alliances mark a new phase in …
Landmark ASCO results and advances in liquid biopsy-driven treatment switching spotlight innovation in cancer research and personalized medicine.
A new configuration of the I-SPY Platform, named I-SPY2.2, introduces sequential multiple-assignment randomization to improve matching of therapy …
Already a subscriber? Log in